PeptideStack
5.2kquestions
20kanswers
220users

semaglutide

Page 8 of 15 · 360 questions tagged semaglutide.

360 questions · sorted by votes · page 8 of 15

20 votes3 answers15k views
What does PIONEER-1 actually establish about mazdutide?

What I am working with: PIONEER-1 · mazdutide. I would like help reading this properly rather than being told what conclusion to reach. I have the full report…

clinical-trials
clinical-trials

Reading the primary literature properly: estimands, intention-to-treat versus per-protocol, confidence intervals, absolute versus relative…

913 questions
semaglutide
semaglutide

A GLP-1 receptor agonist with a fatty-acid-acylated backbone and a roughly one-week half-life, marketed for type 2 diabetes and for weight…

360 questions
cardiovascular
cardiovascular

Cardiovascular outcomes: the SELECT major-adverse-event result, SOUL, SUSTAIN 6 and REWIND, how to convert a hazard ratio into an absolute risk…

111 questions
asked by tamsin_wray 13k · 6 months ago
20 votes 3 answers14k views
What does SURMOUNT-5 actually establish about ecnoglutide?

The particulars: SURMOUNT-5 · ecnoglutide. I have the document in front of me and I can read the numbers. What I cannot do is interpret them. I am reasonably…

clinical-trials
clinical-trials

Reading the primary literature properly: estimands, intention-to-treat versus per-protocol, confidence intervals, absolute versus relative…

913 questions
semaglutide
semaglutide

A GLP-1 receptor agonist with a fatty-acid-acylated backbone and a roughly one-week half-life, marketed for type 2 diabetes and for weight…

360 questions
cardiovascular
cardiovascular

Cardiovascular outcomes: the SELECT major-adverse-event result, SOUL, SUSTAIN 6 and REWIND, how to convert a hazard ratio into an absolute risk…

111 questions
asked by Dr_Priya_Raghunathan 94k · 8 months ago
20 votes0 answers13k views
How comparable are tirzepatide and mazdutide on the evidence available?

The specifics, since they change the answer: tirzepatide · mazdutide. I am trying to choose between two options that are usually discussed as though only one exists.…

clinical-trials
clinical-trials

Reading the primary literature properly: estimands, intention-to-treat versus per-protocol, confidence intervals, absolute versus relative…

913 questions
semaglutide
semaglutide

A GLP-1 receptor agonist with a fatty-acid-acylated backbone and a roughly one-week half-life, marketed for type 2 diabetes and for weight…

360 questions
tirzepatide
tirzepatide

A dual GIP and GLP-1 receptor agonist. Questions here cover the SURPASS and SURMOUNT programmes, the practical differences from a pure GLP-1…

162 questions
survodutide
survodutide

A GLP-1 and glucagon receptor dual agonist with a substantial published MASH dataset. Use this tag for its hepatic endpoints, its dose ladder, and…

14 questions
asked by juan_esquivel 14k · 8 months ago
20 votes 3 answers8.2k views
Does the SURPASS-3 population resemble anyone asking about oral semaglutide here?

Conditions: SURPASS-3 · oral semaglutide. The figures are clear enough; the question is what they mean and what they do not. I can supply the numbers if the specifics…

clinical-trials
clinical-trials

Reading the primary literature properly: estimands, intention-to-treat versus per-protocol, confidence intervals, absolute versus relative…

913 questions
harm-reduction
harm-reduction

Reducing avoidable risk where a decision has already been made: independent verification before use, sterility practice, dose arithmetic checked…

445 questions
semaglutide
semaglutide

A GLP-1 receptor agonist with a fatty-acid-acylated backbone and a roughly one-week half-life, marketed for type 2 diabetes and for weight…

360 questions
asked by bufferline42 49k · 7 months ago
20 votes 5 answers6.4k views
Why do two papers on SURPASS-2 report different headline figures?

This is a question about interpretation, not about whether to act — I will take action questions elsewhere. This is one of those things that everyone repeats and…

clinical-trials
clinical-trials

Reading the primary literature properly: estimands, intention-to-treat versus per-protocol, confidence intervals, absolute versus relative…

913 questions
dosing-math
dosing-math

The arithmetic itself: milligrams to millilitres to insulin units, concentration after reconstitution, dose per draw, and vial-days per vial. Show…

811 questions
semaglutide
semaglutide

A GLP-1 receptor agonist with a fatty-acid-acylated backbone and a roughly one-week half-life, marketed for type 2 diabetes and for weight…

360 questions
asked by colm_dunphy 16k · 16 days ago
20 votes 1 answer5.9k views
Is SURMOUNT-3 a fair comparison of ecnoglutide against its comparator arm?

For reference: SURMOUNT-3 · ecnoglutide. I would like to know whether this claim survives contact with evidence. If the answer is "nobody has tested that", I would…

clinical-trials
clinical-trials

Reading the primary literature properly: estimands, intention-to-treat versus per-protocol, confidence intervals, absolute versus relative…

913 questions
semaglutide
semaglutide

A GLP-1 receptor agonist with a fatty-acid-acylated backbone and a roughly one-week half-life, marketed for type 2 diabetes and for weight…

360 questions
tirzepatide
tirzepatide

A dual GIP and GLP-1 receptor agonist. Questions here cover the SURPASS and SURMOUNT programmes, the practical differences from a pure GLP-1…

162 questions
asked by sasha_ferreira 15k · 5 months ago
20 votes 2 answers4.9k views
How comparable are survodutide and liraglutide on the evidence available?

Concretely: survodutide · liraglutide. These are treated as interchangeable and I do not think they are. If both are acceptable I would like to know that, so I can…

clinical-trials
clinical-trials

Reading the primary literature properly: estimands, intention-to-treat versus per-protocol, confidence intervals, absolute versus relative…

913 questions
semaglutide
semaglutide

A GLP-1 receptor agonist with a fatty-acid-acylated backbone and a roughly one-week half-life, marketed for type 2 diabetes and for weight…

360 questions
tirzepatide
tirzepatide

A dual GIP and GLP-1 receptor agonist. Questions here cover the SURPASS and SURMOUNT programmes, the practical differences from a pure GLP-1…

162 questions
asked by nadia_kowalczyk 14k · 16 days ago
19 votes5 answers22k views
What does SURMOUNT-5 actually establish about orforglipron?

What I have: SURMOUNT-5 · orforglipron. I can parse the result. I am less sure what it licenses me to conclude. I have deliberately not looked at anyone else’s…

clinical-trials
clinical-trials

Reading the primary literature properly: estimands, intention-to-treat versus per-protocol, confidence intervals, absolute versus relative…

913 questions
semaglutide
semaglutide

A GLP-1 receptor agonist with a fatty-acid-acylated backbone and a roughly one-week half-life, marketed for type 2 diabetes and for weight…

360 questions
cardiovascular
cardiovascular

Cardiovascular outcomes: the SELECT major-adverse-event result, SOUL, SUSTAIN 6 and REWIND, how to convert a hazard ratio into an absolute risk…

111 questions
asked by second_lot 11k · 2.2 years ago
19 votes 3 answers21k views
What is the actual legal difference between a 503A and a 503B pharmacy, and what changed when the shortage list changed?

Two pharmacies quoted me for compounded semaglutide last year. One described itself as a "503A compounding pharmacy" and the other as a "503B outsourcing facility",…

compounding
compounding

Compounded preparations: what a 503A and a 503B facility may legally prepare and when, base versus salt forms, beyond-use dating under USP…

61 questions
pharmacy-503a
pharmacy-503a

Section 503A traditional compounding pharmacies specifically: patient-specific prescriptions, accreditation such as PCAB and ACHC, USP 797…

17 questions
semaglutide
semaglutide

A GLP-1 receptor agonist with a fatty-acid-acylated backbone and a roughly one-week half-life, marketed for type 2 diabetes and for weight…

360 questions
telehealth
telehealth

Remote prescribing: what a defensible intake looks like, asynchronous-visit rules, subscription models that bundle a compounded product, and…

14 questions
asked by esther_vandeVelde 49k · 15 months ago
19 votes5 answers20k views
Is ATTAIN-1 a fair comparison of dulaglutide against its comparator arm?

What I have: ATTAIN-1 · dulaglutide. I am asking for verification rather than opinion, ideally with something I can read myself. It is possible the evidence exists…

clinical-trials
clinical-trials

Reading the primary literature properly: estimands, intention-to-treat versus per-protocol, confidence intervals, absolute versus relative…

913 questions
semaglutide
semaglutide

A GLP-1 receptor agonist with a fatty-acid-acylated backbone and a roughly one-week half-life, marketed for type 2 diabetes and for weight…

360 questions
tirzepatide
tirzepatide

A dual GIP and GLP-1 receptor agonist. Questions here cover the SURPASS and SURMOUNT programmes, the practical differences from a pure GLP-1…

162 questions
asked by nominal_ten 14k · 15 months ago
19 votes 5 answers18k views
Does the STEP 2 population resemble anyone asking about oral semaglutide here?

Conditions: STEP 2 · oral semaglutide. I would like to know the limits of what can be inferred from this. What I am trying to avoid is over-reading a single result,…

clinical-trials
clinical-trials

Reading the primary literature properly: estimands, intention-to-treat versus per-protocol, confidence intervals, absolute versus relative…

913 questions
harm-reduction
harm-reduction

Reducing avoidable risk where a decision has already been made: independent verification before use, sterility practice, dose arithmetic checked…

445 questions
semaglutide
semaglutide

A GLP-1 receptor agonist with a fatty-acid-acylated backbone and a roughly one-week half-life, marketed for type 2 diabetes and for weight…

360 questions
asked by orla_sheridan 14k · 18 months ago
19 votes 5 answers17k views
What does PIONEER-1 actually establish about ecnoglutide?

The specifics, since they change the answer: PIONEER-1 · ecnoglutide. I have the document in front of me and I can read the numbers. What I cannot do is interpret…

clinical-trials
clinical-trials

Reading the primary literature properly: estimands, intention-to-treat versus per-protocol, confidence intervals, absolute versus relative…

913 questions
semaglutide
semaglutide

A GLP-1 receptor agonist with a fatty-acid-acylated backbone and a roughly one-week half-life, marketed for type 2 diabetes and for weight…

360 questions
cardiovascular
cardiovascular

Cardiovascular outcomes: the SELECT major-adverse-event result, SOUL, SUSTAIN 6 and REWIND, how to convert a hazard ratio into an absolute risk…

111 questions
asked by swirl_dont_shake 19k · 15 months ago
19 votes 5 answers16k views
What does STEP 4 actually establish about liraglutide?

Concretely: STEP 4 · liraglutide. I would like to know the limits of what can be inferred from this. What I am trying to avoid is over-reading a single result, which…

clinical-trials
clinical-trials

Reading the primary literature properly: estimands, intention-to-treat versus per-protocol, confidence intervals, absolute versus relative…

913 questions
semaglutide
semaglutide

A GLP-1 receptor agonist with a fatty-acid-acylated backbone and a roughly one-week half-life, marketed for type 2 diabetes and for weight…

360 questions
cardiovascular
cardiovascular

Cardiovascular outcomes: the SELECT major-adverse-event result, SOUL, SUSTAIN 6 and REWIND, how to convert a hazard ratio into an absolute risk…

111 questions
asked by j_wierzbicki 45k · 7 months ago
19 votes 5 answers15k views
Is PIONEER-1 a fair comparison of liraglutide against its comparator arm?

Conditions: PIONEER-1 · liraglutide. I want to know whether there is evidence behind this or only repetition. I have checked the obvious registries and monographs…

clinical-trials
clinical-trials

Reading the primary literature properly: estimands, intention-to-treat versus per-protocol, confidence intervals, absolute versus relative…

913 questions
semaglutide
semaglutide

A GLP-1 receptor agonist with a fatty-acid-acylated backbone and a roughly one-week half-life, marketed for type 2 diabetes and for weight…

360 questions
tirzepatide
tirzepatide

A dual GIP and GLP-1 receptor agonist. Questions here cover the SURPASS and SURMOUNT programmes, the practical differences from a pure GLP-1…

162 questions
asked by pip_okonjo 11k · 6 months ago
19 votes0 answers14k views
Is STEP 3 a fair comparison of mazdutide against its comparator arm?

Stated plainly: STEP 3 · mazdutide. This is asserted often enough that I assumed it was established, and then I went looking for the source. I have searched the…

clinical-trials
clinical-trials

Reading the primary literature properly: estimands, intention-to-treat versus per-protocol, confidence intervals, absolute versus relative…

913 questions
semaglutide
semaglutide

A GLP-1 receptor agonist with a fatty-acid-acylated backbone and a roughly one-week half-life, marketed for type 2 diabetes and for weight…

360 questions
tirzepatide
tirzepatide

A dual GIP and GLP-1 receptor agonist. Questions here cover the SURPASS and SURMOUNT programmes, the practical differences from a pure GLP-1…

162 questions
asked by Dr_Signe_Baldursdottir 46k · 13 months ago
19 votes 5 answers12k views
What does STEP 5 actually establish about cagrilintide?

What I am working with: STEP 5 · cagrilintide. I would like help reading this properly rather than being told what conclusion to reach. I have the full report…

clinical-trials
clinical-trials

Reading the primary literature properly: estimands, intention-to-treat versus per-protocol, confidence intervals, absolute versus relative…

913 questions
semaglutide
semaglutide

A GLP-1 receptor agonist with a fatty-acid-acylated backbone and a roughly one-week half-life, marketed for type 2 diabetes and for weight…

360 questions
cardiovascular
cardiovascular

Cardiovascular outcomes: the SELECT major-adverse-event result, SOUL, SUSTAIN 6 and REWIND, how to convert a hazard ratio into an absolute risk…

111 questions
asked by amara_nwachukwu 41k · 13 months ago
19 votes5 answers12k views
Does the SURMOUNT-5 population resemble anyone asking about orforglipron here?

Details up front: SURMOUNT-5 · orforglipron. I can parse the result. I am less sure what it licenses me to conclude. I have deliberately not looked at anyone else’s…

clinical-trials
clinical-trials

Reading the primary literature properly: estimands, intention-to-treat versus per-protocol, confidence intervals, absolute versus relative…

913 questions
harm-reduction
harm-reduction

Reducing avoidable risk where a decision has already been made: independent verification before use, sterility practice, dose arithmetic checked…

445 questions
semaglutide
semaglutide

A GLP-1 receptor agonist with a fatty-acid-acylated backbone and a roughly one-week half-life, marketed for type 2 diabetes and for weight…

360 questions
asked by Dr_Lena_Ostrowska 42k · 3 months ago
19 votes 5 answers12k views
Why do two papers on TRIUMPH-1 report different headline figures?

This is a question about interpretation, not about whether to act — I will take action questions elsewhere. I want to know whether this is a real physical effect or…

clinical-trials
clinical-trials

Reading the primary literature properly: estimands, intention-to-treat versus per-protocol, confidence intervals, absolute versus relative…

913 questions
dosing-math
dosing-math

The arithmetic itself: milligrams to millilitres to insulin units, concentration after reconstitution, dose per draw, and vial-days per vial. Show…

811 questions
semaglutide
semaglutide

A GLP-1 receptor agonist with a fatty-acid-acylated backbone and a roughly one-week half-life, marketed for type 2 diabetes and for weight…

360 questions
asked by rota_site 55k · 5 months ago
19 votes 5 answers8.3k views
How comparable are orforglipron and tirzepatide on the evidence available?

Stated plainly: orforglipron · tirzepatide. I suspect the honest answer is that it depends, in which case I would like to know on what. Assume I can obtain either…

clinical-trials
clinical-trials

Reading the primary literature properly: estimands, intention-to-treat versus per-protocol, confidence intervals, absolute versus relative…

913 questions
semaglutide
semaglutide

A GLP-1 receptor agonist with a fatty-acid-acylated backbone and a roughly one-week half-life, marketed for type 2 diabetes and for weight…

360 questions
tirzepatide
tirzepatide

A dual GIP and GLP-1 receptor agonist. Questions here cover the SURPASS and SURMOUNT programmes, the practical differences from a pure GLP-1…

162 questions
asked by gel_pack_warm 13k · 7 months ago
19 votes 4 answers6.4k views
What does SURMOUNT-1 actually establish about survodutide?

For reference: SURMOUNT-1 · survodutide. I want to understand what this actually establishes, as opposed to what it is being used to imply. My concern is that I am…

clinical-trials
clinical-trials

Reading the primary literature properly: estimands, intention-to-treat versus per-protocol, confidence intervals, absolute versus relative…

913 questions
semaglutide
semaglutide

A GLP-1 receptor agonist with a fatty-acid-acylated backbone and a roughly one-week half-life, marketed for type 2 diabetes and for weight…

360 questions
cardiovascular
cardiovascular

Cardiovascular outcomes: the SELECT major-adverse-event result, SOUL, SUSTAIN 6 and REWIND, how to convert a hazard ratio into an absolute risk…

111 questions
ecnoglutide
ecnoglutide

A long-acting GLP-1 receptor agonist with a cAMP-biased signalling profile. A niche tag, mostly used for mechanism questions about biased agonism…

14 questions
asked by h_villanueva 50k · 5 months ago
19 votes 3 answers6.1k views
Why can I not compare oral and injectable milligram figures at all, even roughly?

I keep seeing people reason like this: oral semaglutide 14 mg daily is 98 mg a week, injectable is 2.4 mg a week, therefore the oral dose is roughly 40 times higher,…

oral-glp1
oral-glp1

Oral routes for GLP-1 receptor agonism: peptide formulations rescued by absorption enhancers such as SNAC, and true small molecules that need no…

14 questions
semaglutide
semaglutide

A GLP-1 receptor agonist with a fatty-acid-acylated backbone and a roughly one-week half-life, marketed for type 2 diabetes and for weight…

360 questions
dosing-math
dosing-math

The arithmetic itself: milligrams to millilitres to insulin units, concentration after reconstitution, dose per draw, and vial-days per vial. Show…

811 questions
titration
titration

Stepwise dose increases over weeks, why the label schedules exist at all, and what tolerability-driven deviation from a schedule looks like in…

444 questions
asked by noor_alhassan 15k · 4 months ago
18 votes 4 answers31k views
How do you actually compute cost per milligram across brand, compounded and research-grade routes?

Every comparison I find online is either a marketing page or someone dividing one number by another with no statement of what the numerator and denominator actually…

cost-analysis
cost-analysis

Cost arithmetic done honestly: cost per milligram after dead-space loss, list versus net price, comparing a multi-dose vial to a fixed-dose pen,…

261 questions
dosing-math
dosing-math

The arithmetic itself: milligrams to millilitres to insulin units, concentration after reconstitution, dose per draw, and vial-days per vial. Show…

811 questions
semaglutide
semaglutide

A GLP-1 receptor agonist with a fatty-acid-acylated backbone and a roughly one-week half-life, marketed for type 2 diabetes and for weight…

360 questions
compounding
compounding

Compounded preparations: what a 503A and a 503B facility may legally prepare and when, base versus salt forms, beyond-use dating under USP…

61 questions
asked by zainab_mustafa 16k · 15 months ago
18 votes 5 answers29k views
Why does my reconstituted semaglutide go cloudy after 3 weeks at 4 °C?

My background is chemistry rather than physiology, which may explain where I am stuck. This is not behaving the way I expected and I want to understand the…

semaglutide
semaglutide

A GLP-1 receptor agonist with a fatty-acid-acylated backbone and a roughly one-week half-life, marketed for type 2 diabetes and for weight…

360 questions
reconstitution
reconstitution

Taking a lyophilised vial to a solution of known concentration: choice of diluent, volume selection, how to add liquid without shearing the cake,…

330 questions
peptide-stability
peptide-stability

The chemistry of peptide degradation: deamidation, oxidation, hydrolysis, aggregation and fibrillation, and how temperature, pH, ionic strength,…

832 questions
endotoxin
endotoxin

Bacterial endotoxin: LAL and kinetic chromogenic methods, how an endotoxin limit is derived from a dose, why endotoxin survives autoclaving, and…

14 questions
asked by Dr_Ingrid_Baumgartner 39k · 14 months ago
18 votes 5 answers27k views
Does the ESSENCE population resemble anyone asking about a GLP-1 receptor agonist here?

Setup, so nobody has to ask: ESSENCE · a GLP-1 receptor agonist. I would like help reading this properly rather than being told what conclusion to reach. I have the…

clinical-trials
clinical-trials

Reading the primary literature properly: estimands, intention-to-treat versus per-protocol, confidence intervals, absolute versus relative…

913 questions
harm-reduction
harm-reduction

Reducing avoidable risk where a decision has already been made: independent verification before use, sterility practice, dose arithmetic checked…

445 questions
semaglutide
semaglutide

A GLP-1 receptor agonist with a fatty-acid-acylated backbone and a roughly one-week half-life, marketed for type 2 diabetes and for weight…

360 questions
asked by ruaidhri_o_shea 51k · 2.3 years ago